Galapagos NV (GLPG)

Market Cap	1.88B +21.2%
Revenue (ttm)	1.31B +303.5%
Net Income	376.76M +333.1%
EPS	5.72 +333.7%
Shares Out	65.90M
PE Ratio	4.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,891
Open	28.81
Previous Close	28.68
Day's Range	28.30 - 28.81
52-Week Range	24.74 - 37.78
Beta	0.15
Analysts	Buy
Price Target	36.50 (+27.44%)
Earnings Date	May 6, 2026

About GLPG

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2005
• Employees: 558
• Stock Exchange: NASDAQ
• Ticker Symbol: GLPG
• Website: https://www.glpg.com

Financial Performance

In 2025, Galapagos NV's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Analyst Summary

According to 2 analysts, the average rating for GLPG stock is "Buy." The 12-month stock price target is $36.5, which is an increase of 27.44% from the latest price.

Price Target

$36.5

(27.44% upside)

Analyst Consensus: Buy